[6-K] Haleon plc American Current Report (Foreign Issuer)

Rhea-AI Filing Summary

Haleon plc reports the purchase and cancellation of 172,878 ordinary shares of £0.01 each under the second tranche of its share buyback programme announced 31 July 2025. Following settlement, registered share capital is 8,952,651,173 ordinary shares, of which 1,580,205 are held as treasury shares, leaving 8,951,070,968 ordinary shares with voting rights. A full breakdown of individual trades is available via the provided RNS link and on the company website.

Insights

Corporate Finance Analyst

TL;DR: A routine tranche of the announced buyback executed; share count modestly reduced with negligible immediate financial impact.

The company executed a repurchase of 172,878 shares for cancellation as part of an ongoing buyback programme. This disclosure provides updated capital and voting share counts, enabling shareholders to assess notification thresholds under FCA rules. The transaction sizes reported on the exchange suggest market execution rather than large block tendering. Given the very small quantity relative to total issued shares, the move is administratively important but not materially value-accretive on its own.

Corporate Governance Specialist

TL;DR: Governance disclosure meets regulatory requirements; transparency on voting share count restored after cancellation.

The filing supplies the required market abuse regulation breakdown link and confirms updated voting share numbers, which are essential for shareholder notification compliance. The cancellation and treasury share figures are clearly stated: registered capital remains at 8,952,651,173 ordinary shares with 1,580,205 treasury shares, yielding 8,951,070,968 voting shares. This is a standard and timely disclosure consistent with good governance and market transparency practices.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2025

Commission File Number: 001-41411

Haleon plc

(Translation of registrant’s name into English)

Building 5, First Floor, The Heights,

Weybridge, Surrey, KT13 0NY

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

EXHIBIT INDEX

Exhibit Number	Description
99.1	11 September 2025 - “Transaction in Own Shares”

99.1

Haleon plc: Transaction in own shares

11 September 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 172,878 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	10 September 2025	10 September 2025	10 September 2025
Number of Shares purchased:	172,878	-	-
Highest price paid per Share (p):	364.0000	-	-
Lowest price paid per Share (p):	363.5000	-	-
Volume weighted average price paid per Share (p):	363.8412	-	-

Following the settlement of the above, the Company's registered share capital is 8,952,651,173 ordinary shares of £0.01 each, of which 1,580,205 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,951,070,968 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.rns-pdf.londonstockexchange.com/rns/8592Y_1-2025-9-10.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Enquiries
Investors		Media
Jo Russell	+44 7787 392441	Zoë Bird	+44 7736 746167
Rakesh Patel	+44 7552 484646	Victoria Durman	+44 7894 505730
Email: investor-relations@haleon.com		Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com. 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		HALEON PLC (Registrant)
Date: September 11, 2025	By:	/s/ Amanda Mellor
		Name:	Amanda Mellor
		Title:	Company Secretary

FAQ

What did Haleon (HLN) announce in this Form 6-K?

Haleon announced the purchase and cancellation of 172,878 ordinary shares under the second tranche of its buyback programme.

How many ordinary shares with voting rights does Haleon have after the transaction?

After settlement, Haleon has 8,951,070,968 ordinary shares with voting rights.

How many treasury shares does Haleon hold following the cancellation?

The company holds 1,580,205 treasury shares as reported in the filing.

Where can I find the full breakdown of individual trades?

A full breakdown is available at the RNS link provided in the announcement: http://www.rns-pdf.londonstockexchange.com/rns/8592Y_1-2025-9-10.pdf and on www.haleon.com/investors.

Does this announcement constitute an offer for securities?

No. The announcement explicitly states it does not constitute an offer or solicitation for securities in any jurisdiction.